Literature DB >> 24560559

CD34 and α smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma.

Kristen M Paral1, Jerome B Taxy2, Mark W Lingen3.   

Abstract

OBJECTIVE: This study evaluated the use of stromal biomarkers CD34 and α smooth muscle actin (α-SMA) to distinguish verrucous carcinoma (VC) from verrucous hyperplasia (VH). STUDY
DESIGN: Thirteen VH, 15 VC, 20 squamous cell carcinoma (SCC), and 16 of uninvolved adjacent stroma specimens were analyzed for α-SMA and CD34 expression by immunohistochemistry.
RESULTS: Stromal α-SMA positivity was observed in 100% (20 of 20) of the SCC and in 93% (14 of 15) of the VC, whereas none of the VH (0 of 13) or adjacent uninvolved stroma (0 of 16) demonstrated α-SMA reactivity. Stromal CD34 positivity was observed in 100% (13 of 13) of VH and adjacent stroma (16 of 16), while 20% (3 of 15) of VC and 11% (2 of 18) of SCC stroma expressed CD34. The SCC and VC groups differed significantly from the VH and uninvolved stroma groups for both α-SMA and CD34 expression (P < .0001).
CONCLUSIONS: Stromal CD34 and α-SMA protein expression patterns may aid in distinguishing between VC and VH in challenging cases.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24560559     DOI: 10.1016/j.oooo.2013.12.401

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  2 in total

Review 1.  Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review.

Authors:  Sepanta Hosseinpour; Fatemeh Mashhadiabbas; Mitra Ghazizadeh Ahsaie
Journal:  Pathol Oncol Res       Date:  2016-12-06       Impact factor: 3.201

Review 2.  Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature.

Authors:  Masroor Hassan; Asim Qureshi; Humaira Nasir
Journal:  BMJ Case Rep       Date:  2016-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.